Lincoln Pharmaceuticals Ltd
NSE:LINCOLN

Watchlist Manager
Lincoln Pharmaceuticals Ltd Logo
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Watchlist
Price: 557.1 INR -1.28% Market Closed
Market Cap: 11.2B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+85%
Revenue
Forecast
+16%
Operating Income
Forecast
+19%
Net Income
Forecast
+16%

Wall Street
Price Targets

LINCOLN Price Targets Summary
Lincoln Pharmaceuticals Ltd

Wall Street analysts forecast LINCOLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LINCOLN is 1 028.16 INR with a low forecast of 1 018.08 INR and a high forecast of 1 058.4 INR.

LINCOLN Lowest Forecast
Wall Street Target
1 018.08 INR
83% Upside
LINCOLN Average Forecast
Wall Street Target
1 028.16 INR
85% Upside
LINCOLN Highest Forecast
Wall Street Target
1 058.4 INR
90% Upside
Lowest
Price Target
1 018.08 INR
83% Upside
Average
Price Target
1 028.16 INR
85% Upside
Highest
Price Target
1 058.4 INR
90% Upside
Lincoln Pharmaceuticals Ltd Competitors:
Price Targets
H
1J5
Hyphens Pharma International Ltd
30% Upside
MYX
Mayne Pharma Group Ltd
6% Upside
SUPRIYA
Supriya Lifescience Ltd
0% Upside
069620
Daewoong Pharma
45% Upside
H
1J5
Hyphens Pharma International Ltd
30% Upside
MYX
Mayne Pharma Group Ltd
6% Upside
SUPRIYA
Supriya Lifescience Ltd
0% Upside
069620
Daewoong Pharma
45% Upside
2161
Jbm (Healthcare) Ltd
10% Upside
M
MBX
MBX Biosciences Inc
243% Upside
S
SDZ
Sandoz Group AG
17% Upside
C
000661
Changchun High & New Technology Industries Group Inc
14% Upside

Revenue
Forecast

Revenue Estimate
Lincoln Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's revenue is 5%. The projected CAGR for the next 3 years is 16%.

5%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lincoln Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's operating income is 12%. The projected CAGR for the next 3 years is 19%.

12%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lincoln Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's net income is 19%. The projected CAGR for the next 3 years is 16%.

19%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-16%
Average Miss
What are analyst estimates?

See Also

Summary
LINCOLN intrinsic value, competitors valuation, and company profile.
DCF Valuation
LINCOLN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LINCOLN stock valuation using valuation multiples.
Wall Street Estimates
LINCOLN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LINCOLN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LINCOLN's stock price target?
Price Target
1 028.16 INR

According to Wall Street analysts, the average 1-year price target for LINCOLN is 1 028.16 INR with a low forecast of 1 018.08 INR and a high forecast of 1 058.4 INR.

What is Lincoln Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's revenue is 5%. The projected CAGR for the next 3 years is 16%.

What is Lincoln Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's operating income is 12%. The projected CAGR for the next 3 years is 19%.

What is Lincoln Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Lincoln Pharmaceuticals Ltd's net income is 19%. The projected CAGR for the next 3 years is 16%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 253,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.